5 th <strong>European</strong> <strong>Congress</strong> <strong>of</strong> <strong>Virology</strong>cells, and virus like particles <strong>of</strong> YFV was expressed in HEK 293T cells.Furthermore, we developed a panel <strong>of</strong> 31 hybridomas against the YFV,among which two monoclonal antibodies were well characterized. Withthese reagents it was possible to standardize two serologic immunoassays(sandwich ELISA) for the detection <strong>of</strong> IgG or IgM directed against YFVproteins in simian and human samples. Recombinant NS1 and VLPs showedto be good antigens for the detection <strong>of</strong> anti YFV immunoglobulins.And the ELISAs with these antigens showed high concordance in reactivitypr<strong>of</strong>iles <strong>of</strong> samples when compared to a similar test using the nativeviral particle as antigen. Besides proving the usefulness <strong>of</strong> the developedtools for diagnosis <strong>of</strong> yellow fever, it was also possible to evidence the presence<strong>of</strong> antibodies against NS1 protein in samples <strong>of</strong> primary vaccinationwith 17DD strain, in contrast with previous literature data.REF 444Real time label free measurement <strong>of</strong> virus infectivityAure SAULNIER 1 , Damien SOULET 1 , Cédric CHARRETIER 2 ,Nolwenn NOUGAREDE 11 Immunological and Microbiological Characterization Platform, AnalyticalR&D EU department, San<strong>of</strong>i Pasteur, Marcy l’Etoile, FRANCE;2 <strong>Virology</strong> and Immunology Platform, Analytical R&D EU department,San<strong>of</strong>i Pasteur, Marcy l’Etoile, FRANCEDifferent basics methods are commonly used to titer viral infectivity. Theseendpoint assays are time consuming and long lasting. Most <strong>of</strong> them arebased on direct examination <strong>of</strong> virus cythopathic effects and a specificvirus staining is <strong>of</strong>ten required to discriminate viral spreading. Real timecell analyzer (RTCA) system was developed to monitor dynamic label freeand non invasive cellular events using microelectronic biosensor technology.In this study, feasibility to use cell sensor technologies to substituteclassical limiting dilution method was evaluated. Large panel <strong>of</strong> virus families,known to be cytopathogenic, lytic or not, was investigated to have arepresentative view <strong>of</strong> the device performance. We compared in two celllines (Vero, MRC5) in parallel classical titration method to the real timeimpedance signal acquired with the xCELLigence RTCA (ACEA Biosciences).A comprehensive representation <strong>of</strong> the cell culture behavior wasobtained: the real time monitoring <strong>of</strong> the biological status <strong>of</strong> cells (cellularindex) showed a virus induced dose dependent impedance drop or changesfollowing infection. The time corresponding to 50% decrease/modulationin cell impedance was inversely proportional to virus infectious dose. Anextrapolation <strong>of</strong> final titers can be made sooner, few days post infection,based on the timing <strong>of</strong> the first impedance drop/modulation, for all virusfamilies tested on at least one cell substrate. We conclude that RTCA systemprovide a broad new tool, quantitative and high throughput, to realtime characterizing viral growth in cell culture.REF 445Utility <strong>of</strong> the QIAGEN artus PCR assays for the detection <strong>of</strong> humanherpes virus genomes in formalin fixed paraffin embedded clinicalsamplesOliver SCHILDGEN, Verena SCHILDGEN, Ramona Liza TILLMANN,Michael BROCKMANNKliniken der Stadt Köln gGmbH, Cologne, GERMANYObjectives: Qualitative and quantitative pathogen detection from formalinfixed paraffin embedded (FFPE) material is a major challenge in moleculardiagnostics, especially if no further unfixed clinical samples are availablefor microbiological or virological diagnostics. Thus the aim <strong>of</strong> the presentstudy was to analyse the utility <strong>of</strong> the artus real time PCR assays for thedetection <strong>of</strong> human herpes viruses (HSV1, HSV2, VZV, CMV, and EBV)in FFPE samples. Methods: Between April 2010 and September 2012we received requests for a total number <strong>of</strong> 91 clinical samples putativelypositive for human herpes viruses. FFPE material was subject to DNAextraction using the QIAGEN FFPE kit (QIAGEN GmbH, Hilden, Germany).PCRs for human herpesviruses were carried out using the artusassays for the detection <strong>of</strong> HSV1/2, EBV, CMV, and VZV according tothe manufacturer’s protocols. Results: In total, 27 samples were tested forHSV1 and HSV2, <strong>of</strong> those 3/27 (11.1%) were positive for HSV1 and 1/27samples was positive for HSV2. Of 50 samples tested for CMV, 6 werepositive (12%). 1/12 samples tested for VZV was positive for VZV and0/2 samples tested for EBV were positive. Conclusions: The PCR resultsshow that human herpes viruses can be detected from FFPE material withcommercial real time assays in an <strong>of</strong>f label manner. These assays have theadvantage to detect small DNA fragments, which are a typical feature <strong>of</strong>DNA extracted from FFPE material.REF 446Evaluation <strong>of</strong> a parechovirus PCR on cerebrospinal fluid samplespreviously considered as PCR negativeEvelyne SCHVOERER 1,2 , Aurélie VELAY 1,2 , Hélène JEULIN 1,2 , SibelBERGER 1 , Chantal FINANCE 1 , Véronique VENARD 11 Centre Hospitalier Universitaire Nancy Brabois, Laboratoire de Vi<strong>rologie</strong>,Vandoeuvre lès Nancy, FRANCE; 2“ Stress, IMmunité, PAthogènes”(SIMPA), EA 7300, Vandoeuvre lès Nancy, FRANCEBackground: It was admitted recently that parechoviruses can beresponsible for meningitis in young children, justifying the research <strong>of</strong>parechoviruses in cerebrospinal fluid (CSF) to explore central nervoussystem syndromes. Aim: We are retrospectively evaluating a PARECHO-VIRUS R Gene PCR (bioMérieux, France), on CSF samples from childrenunder 5 year old, previously considered as negative for enteroviruses.Methods: The study consists <strong>of</strong> analyses performed on 50 CSF samplescollected from January 2012 August 2013. Until now, 36 CSF have beentested for parechovirus. After nucleic acid extraction on easyMAGTM(bioMérieux), PCR amplification (ABI 7500) has been realized with:ENTEROVIRUS R Gene kit, PARECHOVIRUS R Gene Kit, and theSuperscript III reverse transcriptase (RT) supplied with the PARE-CHOVIRUS R Gene Kit combined with the ENTEROVIRUS premix(PARECHOVIRUS R Gene template). Results: Two CSF samples out <strong>of</strong>36 were parechovirus positive. These parechoviruses have been detectedin children <strong>of</strong> less than 1 month old showing fever and typical signs <strong>of</strong>meningitis. Moreover, the combination <strong>of</strong> the ‘PARECHOVIRUS RT’ andthe ENTEROVIRUS premix has permitted the detection <strong>of</strong> enterovirusesin three out <strong>of</strong> 36 CSF samples. Conclusion: The RT supplied with thisPARECHOVIRUS kit allows us to save time when simultaneously usedwith enteroviruses and parechoviruses PCR detection kits. These preliminaryresults have highlighted that enteroviruses could be detected in threepreviously negative CSF samples, and parechoviruses in two additionalsamples.Vi<strong>rologie</strong>, Vol 17, supplément 2, septembre 2013S243
5 th <strong>European</strong> <strong>Congress</strong> <strong>of</strong> <strong>Virology</strong>REF 447Evaluation <strong>of</strong> EBV VCA IgM, VCA IgG and EBNA 1 IgG tests usingnovel Abbott Architect CMIA AssayVlasta STEPANOVA 1 , Lenka PLISKOVA 2 , Miroslav FAJFR 1 ,EvaVEJRAZKOVA 3 , Jan TRBUSEK 41 Inst. Clin. Microbiology,University Hospital and Faculty <strong>of</strong> Medicine,Charles University, Hradec Kralove, CZECH REPUBLIC; 2 Inst. Clin.Biochemistry and Diagnostics,University Hospital and Faculty <strong>of</strong> Medicine,Charles University, Hradec Kralove, CZECH REPUBLIC; 3 IVthClinic <strong>of</strong> Internal Diseases, University Hospital and Faculty <strong>of</strong> Medicine,Charles University, Hradec Kralove, CZECH REPUBLIC; 4 AbbottLaboratories s.r.o., Prague, CZECH REPUBLICThe serologic diagnosis <strong>of</strong> Epstein Barr virus (EBV) infection wasextended by a novel, rapid fully automated chemiluminiscent imunoassayon microparticles, CMIA, Architect, Abbott. The aim <strong>of</strong> our study was todetermine VCA IgM, VCA IgG and EBNA 1 IgG antibodies by Abbotttest and compare the results with those obtained by microplate ELISAtests. Materials,methods: VCA IgM, VCA IgG and EBNA 1 IgG weredetected by CMIA, Architect, Abbott and by microplate ELISA tests, ETIVCA IgM, VCA IgG, DiaSorin, Italy, EBNA 1 IgG, Test Line, CZ in total<strong>of</strong> 405 serum samples (185 males, 220 females, age 5–90, different Dg.).Results: seronegativity accordance <strong>of</strong> Abbott tests with ELISA was in 16to 17 samples, primoinfection in 20 to 21 samples, CMIA VCA IgG andEBNA 1 IgG pozitivity (past infection) accordance in 311 to 317 samples,transient EBV infection in 9 samples to 6 in ELISA, isolated CMIA VCAIgG pozitivity in 19 samples to 8, isolated CMIA EBNA IgG pozitivity in2 samples to 6 in ELISA assays. Cross reactivity <strong>of</strong> VCA IgM with CMVIgM was found in 4 samples in Abbott assay and in 5 samples in ELISA,VCA IgM positivity due to EBV reactivation in 14 samples in Abbottassay to 11 in ELISA, other reactivity was documented in 10 and 14cases in both types <strong>of</strong> tests. The precision <strong>of</strong> Architect CMIA assays wasperfect, the maximum SD was 0,16, maximum CV% 4,67. Conclusion:the discrepancy in results should be confirmed by WB, other tests andsubsequent sample due to patient clinical symptoms. Architect assay<strong>of</strong>fers the automated, rapid, sensitive and specific complete EBV serologytest.with high quality in house EIAs, these new Luminex based antibody assaysappear to be highly sensitive and specific. We next wish to design Luminexbased assays <strong>of</strong> novel types for antimicrobial IgM antibodies, as well asIgG avidity and IgG conformation dependence (“ETS”).REF 449Performance evaluation <strong>of</strong> Rubella and CMV IgG and IgM assaysfrom BioPlex ® 2200 ToRC multiplexed panels (Bio Rad)Marie Josee WENDLING, Hicham BENYELLES, Francoise STOLLKELLERInstitut de Vi<strong>rologie</strong>, Strasbourg, FRANCEObjectives: BioPlex2200 multiplexed ToRC assays <strong>of</strong>fer the ability toreport Toxoplasma, Rubella and CMV results in a single test. The aim <strong>of</strong>this study is to evaluate the performances <strong>of</strong> the BioPlex2200 Rubella andCMV IgG and IgM immunoassays by comparing with our routine method(Liaison ® XL, DiaSorin). Methods: 200 routine samples sent to the laboratoryfor Rubella and CMV testing, 5 Rubella IgM positive samples and 4CMV seroconversion panels were submitted to BioPlex2200 ToRC panels.Results were compared to Liaison ® XL. In case <strong>of</strong> discrepancy, Liaison ®for Rubella IgG and Vidas ® (bioMérieux) for Rubella IgM, CMV IgG andIgM were used to arbitrate. Results: Rubella: The concordance for IgGand IgM is respectively 92.5% and 97.0%.The BioPlex2200 IgG assaymay be more sensitive than the Liaison ® XL assay. Regarding the abilityto detect IgM, BioPlex2200 properly detected 4 samples out <strong>of</strong> 5 (thediscrepant sample result was close to the equivocal range). CMV: Theconcordance for IgG and IgM is respectively 99.0% and 97%. Regardingthe ability to detect seroconversion, BioPlex2200 IgM assay was moresensitive than Liaison ® XL for 2 panels out <strong>of</strong> 4 and less sensitive forone. The BioPlex2200 IgG assay is as performant as Liaison XL. Conclusion:The formulation <strong>of</strong> this kit combining several assays is original andinnovative. The system is easy to use. BioPlex2200 CMV assays performancesare very good on IgG, good on IgM. Both are very good in case <strong>of</strong>seroconversion. BioPlex2200 Rubella IgM assay showed a concordance(97%) equal to the data claimed in the package insert.REF 448Microsphere based multiplex antibody assay for Human ParvovirusB19 and Bocaviruses 1 3Yilin WANG 1 , Lea HEDMAN 1,2 , Arun KUMAR 1 , JonasBLOMBERG 3 , Maija LAPPALAINEN 2 , Maria SÖDERLUNDVENERMO 1 , Klaus HEDMAN 1,21 Department <strong>of</strong> <strong>Virology</strong>, Haartman Institute, University <strong>of</strong> Helsinki,Helsinki, FINLAND; 2 Helsinki University Central Hospital LaboratoryDivision, Helsinki, FINLAND; 3 Section <strong>of</strong> <strong>Virology</strong>, Department <strong>of</strong>Medical Sciences, Uppsala University and Uppsala University Hospital,Uppsala, SWEDENDetection <strong>of</strong> antibodies is widely used in diagnosis <strong>of</strong> autoimmune andinfectious diseases. Conventional antibody detection procedures focuson one or a few microbes at a time. The recently introduced multiplexassay performed in suspension (Luminexcorp, Austin, Texas) may enablethe detection <strong>of</strong> antibodies against 50 100 species <strong>of</strong> microbes simultaneously.The system comprises dyed polystyrene beads and two specificfluorochromes. Up to 100 different beads can carry up to 100 differentanalytes. The beads are detected upon bypassing two distinct barcode readerlasers. Semiquantitative results are obtained as Median FluorescentIntensity (MFI) values. This approach has the potential <strong>of</strong> saving time,labour and cost.We set up IgG assays for human parvovirus B19 and the emerging humanbocaviruses (HBoV) 1 3, using as antigen recombinant virus like particles(VLPs) made up <strong>of</strong> the corresponding capsid proteins (VP2). ComparedREF 450Analytical Performance Characteristics <strong>of</strong> Automated Abbott Real-Time CMV for CMV Quantitation in Plasma and Whole BloodHong “Judy” YU 1 , Shiaolan HO 1 , Sara JONES 1 , Catherine BARRY 1 ,Won CHOI 1 , Erika WEBB 1 , John STEPHENS 1 , Klara ABRAVAYA 1 ,Karin PFEIFER 21 Abbott Molecular Inc., Des Plaines, USA; 2 Abbott GmbH & Co., Wiesbaden,GERMANYObjectives: Abbott RealTime CMV is an integrated real time PCR assayincluding automated sample preparation and real time PCR for the quantitation<strong>of</strong> cytomegalovirus (CMV) in human plasma and whole blood.The assay is intended to monitor CMV viral load in patients undergoingtransplantation. This study established the analytical performance characteristics<strong>of</strong> Abbott RealTime CMV. Methods: Abbott RealTime CMVwas performed on the automated m2000 real time PCR system. Limit <strong>of</strong>detection (LOD), lower limit <strong>of</strong> quantitation (LOQ), linearity, and precisionwere determined using serial dilution panels <strong>of</strong> CMV strain AD169in pooled CMV negative human plasma and whole blood. Assay reproducibilitywas assessed using QCMD external quality control panel and/orAcrometrix OptiQuant ® CMVtc Calibration Panel across 12 labs. Results:Abbott RealTime CMV LOD and LOQ were determined to be 31.20 IU/mlusing the plasma protocol and 62.40 IU/ml using the whole blood protocol.The linearity range was from 31.20 IU/ml to 156 million IU/ml, and 62.40IU/ml to 156 million IU/ml respectively. Assay precision was found to be=0.320 log IU/ml regardless <strong>of</strong> sample prep protocol. Evaluation <strong>of</strong> internalS244 Vi<strong>rologie</strong>, Vol 17, supplément 2, septembre 2013